Profile: Cambrex Corp (CBM.N)
14.39USD
4:01pm EDT
$-0.26 (-1.77%)
$14.65
$14.50
$14.60
$13.64
115,057
40,074
$15.62
$8.85
Cambrex Corporation (Cambrex), incorporated in 1981, is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics. The Company’s business is consisted of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Its products include active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The Company supplies its products and services globally to generic pharmaceutical companies. The Company’s owns 51% stake in Zenara Pharma (Zenara), which focuses on the formulation of final dosage form products. The Company’s products are sold through a combination of direct sales and independent agents.
Cambrex manufactures over 70 generic APIs, in relatively small quantities for use in niche therapeutics. The Company’s business consists of three manufacturing facilities and one research and development (R&D) center. These facilities manufacture pharmaceutical intermediates, APIs and ingredients derived from organic chemistry. The Company, through IEP GmbH (IEP), designs and licenses biocatalytic enzymes.
Company Address
Cambrex Corp
ONE MEADOWLANDS PLAZA
EAST RUTHERFORD NJ 7073
P: +1201.8043000
F: +1201.8049852
Company Web Links
| Name | Compensation |
|---|---|
John Miller |
-- |
Steven Klosk |
2,641,000 |
Shlomo Yanai |
-- |
Gregory Sargen |
1,591,740 |
Paolo Russolo |
1,104,610 |

